Sun Pharma Must Get Court Nod Before Launching Semaglutide Tablets
The Delhi High Court ordered Sun Pharma to obtain court approval before launching its semaglutide tablets, after Novo Nordisk filed a patent infringement plea. Sun argues the court lacks territorial jurisdiction and the relevant patent has expired. The ruling stalls Sun’s entry into the growing GLP‑1 market and underscores India’s tightening patent enforcement.